Michael R Bristow

Author:

Michael Jamieson Bristow

ISBN #:

0304368261

US Patent:

6706686, Mar 16, 2004

Filed:

Sep 26, 2002

Appl. No.:

10/256221

Inventors:

Carlin Long - Denver CO
Eric N. Olson - Dallas TX
Michael Bristow - Cherry Hills Village CO
Timothy A. McKinsey - Broomfield CO

Assignee:

The Regents of the University of Colorado - Boulder CO

International Classification:

A61K 3800

US Classification:

514 10, 514307, 514357, 514475, 514618, 514654, 436 63, 424 92

Abstract:

The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.

US Patent:

6946441, Sep 20, 2005

Filed:

Mar 16, 2004

Appl. No.:

10/801985

Inventors:

Carlin Long - Denver CO, US
Eric N. Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy A. McKinsey - Broomfield CO, US

Assignee:

Regents of the University of Colorado, A Body Corporation - Boulder CO
The Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K038/00
A61K031/47
A61K031/44
A61K031/335
A61K031/165

US Classification:

514 10, 514307, 514357, 514475, 514618, 514654

Abstract:

The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.

US Patent:

7049066, May 23, 2006

Filed:

Oct 1, 2001

Appl. No.:

09/969086

Inventors:

Michael R. Bristow - Greenwood Village CO, US
Leslie A. Leinwand - Boulder CO, US
Wayne Minobe - Golden CO, US
Koichi Nakao - Kumamoto, JP
Koichiro Kinugawa - Denver CO, US

Assignee:

The Regents of the University of Colorado - Boulder CO

International Classification:

C12Q 1/68
C12P 19/34
G01N 33/53
C07H 21/04

US Classification:

435 6, 435 71, 435 911, 435 912, 536 231, 536 243

Abstract:

The present invention provides methods of diagnosing myocardial failure in a human. The methods comprise obtaining a sample of myocardial tissue from a ventricle of the heart. In one embodiment, the expression of α-myosin heavy chain, β-myosin heavy chain, or both, are quantitated and their expression levels compared to that seen normal human ventricular myocardial tissues. In another embodiment, the expression of α1-thyroid hormone receptor, α2-thyroid hormone receptor, a α1-thyroid hormone receptor+β1-thyroid hormone receptor, or combinations thereof, are quantitated, and their expression levels compared to that seen normal human ventricular myocardial tissues. Therapeutic interventions based on altering the expression of the aforementioned genes also are provide.

US Patent:

7482331, Jan 27, 2009

Filed:

Apr 25, 2000

Appl. No.:

09/558472

Inventors:

Michael R. Bristow - Greenwood Village CO, US
Leslie A. Leinwand - Boulder CO, US
Wayne Minobe - Golden CO, US
Koichi Nakao - Kumamoto, JP

Assignee:

The Regents of the University of Colorado - Boulder CO

International Classification:

A01N 43/04
C12N 15/63
C07H 21/04

US Classification:

514 44, 435455, 536 235

Abstract:

The invention provides a method of treating myocardial failure in a human. The method comprises administering an effective amount of transgene encoding α-MHC that directly causes an increase in the quantity of α-MHC in the myocardial tissue of the heart.

US Patent:

7678824, Mar 16, 2010

Filed:

Sep 14, 2005

Appl. No.:

11/226908

Inventors:

Stephen B. Liggett - Clarksville MD, US
Michael Bristow - Englewood CO, US

Assignee:

The Regents of the University of Colorado, A Body Corporate - Boluder CO

International Classification:

A61K 31/405
A61P 43/00
C12Q 1/68
C07H 21/02
C07H 21/04
G01N 33/53
A61K 47/00

US Classification:

514415, 514789, 435 6, 435 71, 536 235, 536 2431

Abstract:

The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).

US Patent:

8080578, Dec 20, 2011

Filed:

Aug 13, 2007

Appl. No.:

11/838131

Inventors:

Stephen B. Liggett - Clarksville MD, US
Michael Bristow - Englewood CO, US

Assignee:

The Regents of the University of Colorado, a body corporate - Denver CO

International Classification:

A61K 31/405
A61K 47/00
A61P 43/00
C12Q 1/68
C07H 21/02
C07H 21/04
G01N 33/53

US Classification:

514415, 514789, 435 61, 435 611, 435 617, 435 71, 536 235, 536 2431, 530350

Abstract:

The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).

US Patent:

8093286, Jan 10, 2012

Filed:

Aug 13, 2007

Appl. No.:

11/838142

Inventors:

Stephen B. Liggett - Clarksville MD, US
Michael Bristow - Englewood CO, US

Assignee:

The Regents of the University of Colorado, a body corporate - Denver CO

International Classification:

A61K 31/405
A61K 47/00
A61P 43/00
C12Q 1/68
C07H 21/02
C07H 21/04
G01N 33/53

US Classification:

514415, 514789, 435 61, 435 611, 435 617, 435 71, 536 235, 536 2431, 530350

Abstract:

The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).

US Patent:

20030096782, May 22, 2003

Filed:

Sep 11, 2002

Appl. No.:

10/241368

Inventors:

Michael Bristow - Cherry Hills Village CO, US
Wayne Minobe - Golden CO, US
Brian Lowes - Denver CO, US
M. Perryman - Denver CO, US

Assignee:

The Regents of the University of Colorado

International Classification:

A61K048/00
C12Q001/68

US Classification:

514/044000, 435/006000

Abstract:

Methods for the identification of genes involved in cardiac disease states are provided. The methods compare gene expression between diseased and therapeutically treated patients. Through the identification of new targets, additional methods for drug screening and therapy also are provided.